Nabla Bio Innovates AI-Driven Antibody Design Amidst Protein Engineering Boom
Nabla Bio is advancing towards the development of AI-generated antibodies, leveraging protein-making AI models that have already contributed to a $1 billion startup and a Nobel Prize win in 2024. This progress highlights the potential of AI in revolutionizing biotechnology and therapeutic development.